| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Taisho Pharmaceutical Holdings Co. Ltd (OTCGREY: TAISF)
TAISF Technical Analysis
5
| As on 3rd Jan 2024 TAISF STOCK Price closed @ 59.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 63.85 & Strong Sell for SHORT-TERM with Stoploss of 63.92 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TAISFSTOCK Price
| Open | 59.00 | Change | Price | % |
| High | 59.00 | 1 Day | -0.23 | -0.39 |
| Low | 59.00 | 1 Week | 18.15 | 44.43 |
| Close | 59.00 | 1 Month | 11.70 | 24.74 |
| Volume | 100 | 1 Year | -6.30 | -9.65 |
| 52 Week High 69.00 | 52 Week Low 35.70 | ||||
OTCGREY USA Most Active Stocks
| IARED | 24.62 | % |
| BLBRF | 0.11 | % |
| GCEA | 29.00 | -21.20% |
| AHLD | 82.75 | -2.93% |
| MAXC | 1.78 | 0.00% |
| KAKZF | 110.12 | 4.72% |
| MNSLV | 25.50 | 1.03% |
| GXRFF | 0.04 | -20.00% |
| ISVQF | 5.72 | 0.18% |
| JRVMF | 0.01 | 0.00% |
OTCGREY USA Top Gainers Stocks
OTCGREY USA Top Losers Stocks
| TAISF Daily Charts |
TAISF Intraday Charts |
Whats New @ Bazaartrend |
TAISF Free Analysis |
|
|
TAISF Important Levels Intraday
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
| RESISTANCE | 59.00 |
TAISF Forecast June 2024
| 4th UP Forecast | 69.79 |
| 3rd UP Forecast | 66.33 |
| 2nd UP Forecast | 64.19 |
| 1st UP Forecast | 62.05 |
| 1st DOWN Forecast | 55.95 |
| 2nd DOWN Forecast | 53.81 |
| 3rd DOWN Forecast | 51.67 |
| 4th DOWN Forecast | 48.21 |
TAISF Weekly Forecast
| 4th UP Forecast | 65.36 |
| 3rd UP Forecast | 63.32 |
| 2nd UP Forecast | 62.06 |
| 1st UP Forecast | 60.80 |
| 1st DOWN Forecast | 57.20 |
| 2nd DOWN Forecast | 55.94 |
| 3rd DOWN Forecast | 54.68 |
| 4th DOWN Forecast | 52.64 |
TAISF Forecast2024
| 4th UP Forecast | 123.46 |
| 3rd UP Forecast | 102.79 |
| 2nd UP Forecast | 90.01 |
| 1st UP Forecast | 77.23 |
| 1st DOWN Forecast | 40.77 |
| 2nd DOWN Forecast | 27.99 |
| 3rd DOWN Forecast | 15.21 |
| 4th DOWN Forecast | -5.46 |
Taisho Pharmaceutical Holdings Co. Ltd ( OTCGREY USA Symbol : TAISF )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
TAISF Business Profile
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan. Address: 3-24-1 Takada, Tokyo, Japan, 170-8655
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service